Entity Central Index Key
Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Shell Company
Entity Shell Company
Title of 12(b) Security
Security12b Title
Security Exchange Name
Security Exchange Name
Entity File Number
Entity File Number
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Document Quarterly Report
Document Quarterly Report
Document Transition Report
Document Transition Report
Entity Common Stock Shares Outstanding
Entity Common Stock Shares Outstanding
Restricted time deposits noncurrent.
Lease obligations noncurrent.
Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Short-term investments
Short Term Investments
Accounts receivable, net ($4,715 and $4,845 from a related party)
Accounts Receivable Net Current
Inventories
Inventory Net
Prepaid expenses and other current assets ($165 and $125,210 from related parties)
Prepaid Expense And Other Assets Current
Total current assets
Assets Current
Restricted time deposits
Restricted Time Deposits Noncurrent
Long-term investments
Long Term Investments
Property and equipment, net
Property Plant And Equipment Net
Finance lease right-of-use assets
Finance Lease Right Of Use Asset
Other assets ($1,483 and $0 from a related party)
Other Assets Noncurrent
Total assets
Assets
Liabilities, stockholders’ equity and non-controlling interests
Liabilities And Stockholders Equity [Abstract]
Current liabilities:
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued and other current liabilities ($4,135 and $36,883 to a related party)
Accrued Liabilities And Other Liabilities
Deferred revenue
Contract With Customer Liability Current
Finance lease liabilities, current
Finance Lease Liability Current
Total current liabilities
Liabilities Current
Long-term portion of lease obligations
Lease Obligations Noncurrent
Product development obligations
Accrued Product Development Costs
Deferred revenue, net of current
Contract With Customer Liability Noncurrent
Finance lease liabilities, non-current
Finance Lease Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and Contingencies (Note 10)
Commitments And Contingencies
Stockholders’ equity:
Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019
Preferred Stock Value
Common stock, $0.01 par value; 225,000 shares authorized at September 30, 2020 and December 31, 2019; 90,885 and 87,657 shares issued and outstanding at September 30, 2020 and December 31, 2019
Common Stock Value
Additional paid-in capital
Additional Paid In Capital
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income Loss Net Of Tax
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders’ equity
Stockholders Equity
Non-controlling interests
Minority Interest
Total equity
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
Total liabilities, stockholders’ equity and non-controlling interests
Liabilities And Stockholders Equity
Accounts receivable from related party
Accounts Receivable Related Parties Current
Prepaid expenses and other current assets from related parties
Due From Related Parties Current
Other assets from related party
Due From Related Parties Noncurrent
Accrued and other current liabilities to related party
Due To Related Parties Current
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, shares authorized
Preferred Stock Shares Authorized
Preferred stock, shares issued
Preferred Stock Shares Issued
Preferred stock, shares outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, shares issued
Common Stock Shares Issued
Common stock, shares outstanding
Common Stock Shares Outstanding
Cost of goods and services sold operating expense.
Interest and other net.
Income Statement [Abstract]
Statement [Table]
Statement [Table]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
License Revenue [Member]
License [Member]
Development and other revenue.
Development and Other Revenue [Member]
Development And Other Revenue [Member]
Product Revenue, Net [Member]
Product [Member]
Drug product revenue.
Drug Product Revenue [Member]
Drug Product Revenue [Member]
Statement [Line Items]
Statement [Line Items]
Revenue:
Revenue From Contract With Customer [Abstract]
Total revenue
Revenue From Contract With Customer Excluding Assessed Tax
Operating costs and expenses:
Operating Costs And Expenses [Abstract]
Cost of goods sold
Cost Of Goods And Services Sold Operating Expense
Cost, Product and Service [Extensible List]
Type Of Cost Good Or Service Extensible List
Research and development
Research And Development Expense
Selling, general and administrative
Selling General And Administrative Expense
Total operating costs and expenses
Operating Expenses
Income (loss) from operations
Operating Income Loss
Interest and other, net
Interest And Other Net [Abstract]
Interest expense
Interest Expense
Interest income and other, net (includes $(13), $0, $(13) and $0 from a related party)
Interest And Other Income
Total interest and other, net
Interest Income Expense Nonoperating Net
Income (loss) before income taxes
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Provision for income taxes
Income Tax Expense Benefit
Net income (loss)
Net Income Loss
Net income (loss) per share:
Earnings Per Share Basic And Diluted [Abstract]
Basic
Earnings Per Share Basic
Diluted
Earnings Per Share Diluted
Weighted average number of common shares used to calculate net income (loss) per share:
Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]
Basic
Weighted Average Number Of Shares Outstanding Basic
Diluted
Weighted Average Number Of Diluted Shares Outstanding
Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.
Drug product revenue from related party.
Interest and other income from related party.
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Astellas agreements.
Astellas Agreement [Member]
Astellas Collaboration Agreement [Member]
License and milestone revenue from a related party
License Fees And Milestones Revenue
Collaboration services and other revenue from a related party
Collaboration Services And Other Revenue
Drug product revenue from a related party
Drug Product Revenue From Related Party
Interest income and other net from related party
Interest And Other Income From Related Party
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)
Other comprehensive income (loss):
Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]
Foreign currency translation adjustments (Note 1)
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
Available-for-sale investments:
Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]
Unrealized gain (loss) on investments, net of tax effect
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Other comprehensive income (loss), net of taxes
Other Comprehensive Income Loss Net Of Tax
Comprehensive income (loss)
Comprehensive Income Net Of Tax
Shares issued from stock plans net of payroll taxes paid shares.
Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.
Statement Of Stockholders Equity [Abstract]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Retained Earnings [Member]
Noncontrolling Interests [Member]
Noncontrolling Interest [Member]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Axis]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Domain]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Accounting Standards Update
Adjustments For New Accounting Pronouncements [Axis]
Accounting Standards Update
Type Of Adoption [Member]
ASU 2016-02 [Member]
Accounting Standards Update201602 [Member]
ASU 2018-02 [Member]
Accounting Standards Update201802 [Member]
Balance
Balance, Shares
Shares Outstanding
Change in unrealized gain or loss on investments
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
Foreign currency translation adjustments
Shares issued from stock plans, net of payroll taxes paid
Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
Shares issued from stock plans, net of payroll taxes paid, Shares
Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Balance
Balance, Shares
Unrealized loss (gain) on equity investments.
Investment loss in unconsolidated variable interest entity.
Increase (decrease) in accrued interest for finance lease liabilities.
Payments to acquire available for sale securities and term deposit.
Repayments of finance lease liabilities.
Statement Of Cash Flows [Abstract]
Operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net income (loss)
Profit Loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation
Depreciation
Amortization of finance lease right-of-use assets
Finance Lease Right Of Use Asset Amortization
Net accretion of discount on investments
Accretion Amortization Of Discounts And Premiums Investments
Unrealized loss on equity investments
Unrealized Loss Gain On Equity Investments
Investment loss in unconsolidated variable interest entity
Investment Loss In Unconsolidated Variable Interest Entity
Gain on disposal of property and equipment
Gain Loss On Disposition Of Assets
Stock-based compensation
Share Based Compensation
Realized loss on sales of available-for-sale securities
Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
Changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable, net
Increase Decrease In Accounts Receivable
Inventories
Increase Decrease In Inventories
Prepaid expenses and other current assets
Increase Decrease In Prepaid Deferred Expense And Other Assets
Other assets
Increase Decrease In Other Operating Assets
Accounts payable
Increase Decrease In Accounts Payable
Accrued and other liabilities
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Accrued interest for finance lease liabilities
Increase Decrease In Accrued Interest For Finance Lease Liabilities
Other long-term liabilities
Increase Decrease In Other Noncurrent Liabilities
Net cash provided by (used in) operating activities
Net Cash Provided By Used In Operating Activities
Investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Purchases of property and equipment
Payments To Acquire Property Plant And Equipment
Payment made for acquisition
Payments To Acquire Businesses Gross
Purchases of available-for-sale securities and term deposit
Payments To Acquire Available For Sale Securities And Term Deposit
Proceeds from sales of available-for-sale securities
Proceeds From Sale Of Available For Sale Securities
Proceeds from maturities of investments
Proceeds From Sale Maturity And Collections Of Investments
Net cash provided by (used in) investing activities
Net Cash Provided By Used In Investing Activities
Financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Repayments of finance lease liabilities
Repayments Of Finance Lease Liabilities
Repayments of lease obligations
Repayments Of Debt And Capital Lease Obligations
Cash paid for payroll taxes on restricted stock unit releases
Payments Related To Tax Withholding For Share Based Compensation
Proceeds from issuance of common stock
Proceeds From Issuance Of Common Stock
Net cash provided by (used in) financing activities
Net Cash Provided By Used In Financing Activities
Effect of exchange rate change on cash and cash equivalents
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Net increase (decrease) in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Total cash and cash equivalents at beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Total cash and cash equivalents at end of period
Accounting Policies [Abstract]
Significant Accounting Policies
Significant Accounting Policies [Text Block]
Acquisition and variable interest entity.
Acquisition and variable interest entity abstract.
Acquisition And Variable Interest Entity [Abstract]
Acquisition and Variable Interest Entity
Acquisition And Variable Interest Entity [Text Block]
Collaborative arrangement and revenues.
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration Agreements and Revenues
Collaborative Arrangement And Revenues Disclosure [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Leases [Abstract]
Leases
Leases Of Lessee Disclosure [Text Block]
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Description of operations policy.
Description of Operations
Description Of Operations Policy Policy [Text Block]
Basis of presentation and principles of consolidation policy.
Basis of Presentation and Principles of Consolidation
Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]
Out of period adjustments policy.
Out-of-Period Adjustments
Out Of Period Adjustments Policy
Use of Estimates
Use Of Estimates
Net Income (Loss) per Share
Earnings Per Share Policy [Text Block]
Risks and uncertainties.
Risks and Uncertainties
Risks And Uncertainties Policy [Text Block]
Recently issued and adopted accounting guidance.
Recently Issued and Adopted Accounting Guidance
Recently Issued And Adopted Accounting Guidance Policy [Text Block]
Recently issued accounting guidance not yet adopted.
Recently Issued Accounting Guidance Not Yet Adopted
Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]
Collaboration Arrangements and Revenues
Collaborative Arrangement Accounting Policy
Product revenue policy.
Product Revenue
Product Revenue Policy Policy [Text Block]
Drug product revenue.
Drug Product Revenue
Drug Product Revenue Policy [Text Block]
Other revenues policy.
Other Revenues
Other Revenues Policy [Text Block]
Deferred Revenue
Revenue From Contract With Customer Policy [Text Block]
Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation
Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]
Contract with customer milestone method.
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
Japan [Member]
JAPAN
Europe [Member]
Europe [Member]
United States/Rest of World and China.
U.S./RoW and China [Member]
United States Rest Of World And China [Member]
Summary of Revenue Recognized under Agreement
Contract With Customer Milestone Method Table [Text Block]
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue
Disaggregation Of Revenue Table [Text Block]
Roll-forward of Contract Liabilities
Contract With Customer Asset And Liability Table [Text Block]
Summary of Contra-Accounts Receivable Items Related to Product Revenue
Accounts Receivable Allowance For Credit Loss Table [Text Block]
Schedule of drug product revenue.
Schedule of Drug Product Revenue
Schedule Of Drug Product Revenue Table [Text Block]
Fair Values of Financial Assets Measured on Recurring Basis
Fair Value Assets Measured On Recurring Basis [Text Block]
Fair Values of Financial Liabilities Carried at Historical Cost
Fair Value Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]
Schedule of lease assets and related lease liabilities.
Schedule of Lease Assets and Related Lease Liabilities
Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]
Components of Lease Expense
Lease Cost Table [Text Block]
Schedule of supplemental cash flow information related to leases.
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of lease term and discount rate.
Schedule of Lease Term and Discount Rate
Schedule Of Lease Term And Discount Rate Table [Text Block]
Schedule of maturities of finance and operating leases liabilities.
Schedule of Maturities of Finance and Operating Leases Liabilities
Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]
Schedule of Cash and Cash Equivalents
Schedule Of Cash And Cash Equivalents Table [Text Block]
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments
Schedule Of Available For Sale Securities Reconciliation Table [Text Block]
Schedule of Inventory
Schedule Of Inventory Current Table [Text Block]
Schedule of Prepaid Expenses and Other Current Assets
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]
Schedule of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of Accrued and Other Current Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Schedule of Other Long-term Liabilities
Other Noncurrent Liabilities Table [Text Block]
Schedule of Recorded Stock-Based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.
Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan
Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]
Number of operating segment
Number Of Operating Segments
Increase decrease in revenue due to out of period adjustments.
Immaterial error correction
Immaterial Error Correction
Decrease in revenue due to out of period adjustments
Increase Decrease In Revenue Due To Out Of Period Adjustments
Earnings Per Share [Abstract]
Dilutive effect of potential common shares
Weighted Average Number Diluted Shares Outstanding Adjustment
Diluted
Anti-dilutive shares outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Currency translation adjustment
Translation Adjustment Functional To Reporting Currency Net Of Tax
Description of payment term
Revenue Performance Obligation Description Of Payment Terms
Description of sales return.
Description of sales return
Description Of Sales Return
Acquisition and variable interest entity line items.
Acquisition and variable interest entity table.
Acquisition And Variable Interest Entity [Table]
Acquisition And Variable Interest Entity [Table]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Beijing Kangda Yongfu Pharmaceutical Co., LTD.
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]
Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
FibroGen Beijing.
FibroGen Beijing [Member]
Fibro Gen Beijing [Member]
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Acquired license.
Acquired License [Member]
Acquired License [Member]
Investments by Consolidated and Nonconsolidated Entities
Investments By Consolidated And Nonconsolidated Entities [Axis]
Investments by Consolidated and Nonconsolidated Entities
Investments By Consolidated And Nonconsolidated Entities [Domain]
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Beijing Falikang Pharmaceutical Co Ltd [Member]
Related Party Transaction
Related Party Transaction [Axis]
Related Party Transaction
Related Party Transaction [Domain]
AstraZeneca AB.
AstraZeneca AB [Member]
Astra Zeneca A B [Member]
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Prepaid Expenses and Other Current Assets [Member]
Prepaid Expenses And Other Current Assets [Member]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event [Member]
Acquisition And Variable Interest Entity [Line Items]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares acquired
Business Acquisition Percentage Of Voting Interests Acquired
Cash consideration
Transaction costs
Business Acquisition Cost Of Acquired Entity Transaction Costs
Acquisition costs
Business Combination Acquisition Related Costs
Entire purchase price
Business Combination Consideration Transferred1
Percentage of outstanding shares of acquiree sold by acquirer.
Percentage of outstanding shares sold in exchange for cash consideration
Percentage Of Outstanding Shares Of Acquiree Sold By Acquirer
Cash consideration for exchange of outstanding shares
Equity Method Investment Sold Carrying Amount
Percentage of outstanding shares owned
Variable Interest Entity Ownership Percentage
Investment
Equity Method Investments
Receivable
Related Party Transaction Due From To Related Party
Cash consideration received
Proceeds From Sale Of Equity Method Investments
Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.
Represents the amount of milestone payments related to commercial sales under the collaborative agreement.
The amount of additional consideration based on net sales of product as defined under a collaboration agreement.
Amount of aggregate consideration receivable under collaborative arrangement.
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others Type [Domain]
Clinical development milestone.
Clinical and Development Milestone [Member]
Clinical Development Milestones [Member]
Regulatory milestone.
Regulatory Milestone [Member]
Regulatory Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received
Proceeds From Upfront Non Contingent And Time Based Payments
Potential milestone payments
Potential Milestones
Commercial sales milestone
Commercial Sales Milestone
Additional consideration based on net sales description
Additional Consideration Based On Net Sales
Aggregate consideration received
Collaborative Arrangement Aggregate Consideration
Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.
Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.
Development and regulatory approval milestones
Development And Regulatory Approval Milestones
Percentage of joint development costs committed to fund
Percentage Of Funding For Costs
Transaction price allocated to performance obligations.
Transaction price and allocated to performance obligations
Transaction Price Allocated To Performance Obligations
Revenue during period from performance obligations
Revenue Remaining Performance Obligation
Milestone payment received
Contract With Customer Liability Revenue Recognized
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Development milestone payment received.
Astra Zeneca agreements.
AstraZeneca Agreements [Member]
Astra Zeneca Agreements [Member]
United states and rest of world.
U.S./RoW [Member]
United States And Rest Of World [Member]
Deferred approval milestone.
Deferred Approval Milestone [Member]
Deferred Approval Milestone [Member]
Development milestones.
Development Milestones [Member]
Development Milestones [Member]
New drug application submission milestone.
NDA Submission Milestone [Member]
New Drug Application Submission Milestone [Member]
China [Member]
CHINA
Other Noncurrent Liabilities
Other Noncurrent Liabilities [Member]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Selling, General and Administrative Expenses [Member]
Selling General And Administrative Expenses [Member]
Upfront, non-contingent, non-refundable and time-based payments
Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments
Receipt of development milestone payment
Development Milestone Payment Received
Unbilled contract asset
Supplies
Estimated joint development extended service period.
Estimated joint development extended service period
Estimated Joint Development Extended Service Period
Commercial sales and other events milestone.
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Collaborative arrangement aggregate consideration for milestone and upfront payments.
Proceeds from upfront, non-contingent and non-refundable payments
Proceeds From Upfront Non Contingent And Non Refundable Payments
Commercial sales and other events milestone
Commercial Sales And Other Events Milestone
Aggregate consideration received for milestone and upfront payments
Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments
Reversal of accrued co-promotion expenses.
Co-promotion expenses.
Historical co-promotion costs.
Accrued long term co promotion liability non current.
Accrued long term co promotion liability current.
Historical co-promotion costs
Historical Co Promotion Costs
Reversal of accrued co-promotion expenses
Reversal Of Accrued Co Promotion Expenses
Co-promotion expenses
Co Promotion Expenses
Accrued long-term co-promotion expenses
Accrued Long Term Co Promotion Liability Non Current
Accrued long term co promotion liability current
Accrued Long Term Co Promotion Liability Current
Changes in revenue due to prior period adjustment of performance obligations
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
Revenue Recognition Multiple Deliverable Arrangements [Table]
Revenue Recognition Multiple Deliverable Arrangements [Table]
Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.
License [Member]
Co development information sharing and committee services.
Co-development, information sharing & committee services [Member]
Co Development Information Sharing And Committee Services [Member]
China performance obligation.
China performance obligation [Member]
China Performance Obligation [Member]
Cumulative Revenue
Cumulative Revenue License And Development Revenue Recognized
Deferred Revenue
Contract With Customer Liability
Total Consideration
Cash Consideration Received Under Collaboration Agreement
Variable consideration payment received from estimated future co-development billing.
Remainder of transaction price, variable consideration from estimated future co-development billing
Variable Consideration Payment Received From Estimated Future Co Development Billing
Revenue gross from contract with customer excluding assessed tax.
Disaggregation Of Revenue [Abstract]
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Product [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves Type
Valuation Allowances And Reserves Type [Axis]
SEC Schedule, 12-09, Valuation Allowances and Reserves
Valuation Allowances And Reserves [Domain]
Non-key account hospital listing award.
Non-key Account Hospital Listing Award [Member]
Non Key Account Hospital Listing Award [Member]
Contractual sales rebate.
Contractual Sales Rebate [Member]
Contractual Sales Rebate [Member]
Other discounts and rebates.
Other Discounts and Rebates [Member]
Other Discounts And Rebates [Member]
Sales Return [Member]
Sales Returns And Allowances [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Gross revenue
Revenue Gross From Contract With Customer Excluding Assessed Tax
Rebates and discounts.
Rebates and Discounts [Member]
Rebates And Discounts [Member]
Gross accounts receivable.
Gross Accounts Receivable [Member]
Gross Accounts Receivable [Member]
Contract liabilities,
Contract Liabilities [Member]
Contract Liabilities [Member]
Contract with customer liability additions.
Contract with customer liability deduction.
Contract with customer, liability, increase (decrease) from current translation and other.
Contract with customer liability gross.
Contract with customer liability net of accounts receivable.
Contract with customer liability.
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract with Customer Liability [Line Items]
Contract With Customer Liability [Line Items]
Beginning balance
Additions
Contract With Customer Liability Additions
Deduction
Contract With Customer Liability Deduction
Currency Translation and Other
Contract With Customer Liability Increase Decrease From Current Translation And Other
Gross Contract Liabilities Balance
Contract With Customer Liability Gross
Balance Presented Net Against Accounts Receivable
Contract With Customer Liability Net Of Accounts Receivable
Ending balance
Price adjustment.
Price Adjustment
Price Adjustment [Member]
Provision for credit loss,
Provision for Credit Loss [Member]
Provision For Credit Loss [Member]
Total reductions to gross accounts receivable
Allowance For Doubtful Accounts Receivable
Astellas agreement.
Astellas Agreement
Astellas Agreement [Member]
Drug product revenue
Drug product revenue recognized
Contract with Customer, Liability [Abstract]
Contract With Customer Liability [Abstract]
Deferred revenue
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value Measurements Recurring [Member]
Level 1 [Member]
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 1 [Member]
Fair Value Inputs Level1 [Member]
Level 2 [Member]
Fair Value Inputs Level2 [Member]
Level 3 [Member]
Fair Value Inputs Level3 [Member]
Investment Type
Investment Type [Axis]
Investments
Investment Type Categorization [Member]
U.S. treasury notes and bills [Member]
U S Treasury Securities [Member]
Bond and mutual funds.
Bond and mutual funds [Member]
Bond And Mutual Funds [Member]
Equity investments [Member]
Equity Securities [Member]
Money market funds [Member]
Money Market Funds [Member]
Certificate of deposit [Member]
Certificates Of Deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments
Available For Sale Securities
Assets fair value disclosure
Cash And Cash Equivalents Fair Value Disclosure
Total fair value of financial assets
Assets Fair Value Disclosure
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Lease obligations.
Lease obligations [Member]
Lease Obligations [Member]
Liabilities fair value disclosure
Liabilities Fair Value Disclosure
Transfers of assets from level 1 to 2
Fair Value Assets Level1 To Level2 Transfers Amount
Transfers of assets from level 2 to 1
Fair Value Assets Level2 To Level1 Transfers Amount
Transfers of liabilities from level 1 to 2
Fair Value Liabilities Level1 To Level2 Transfers Amount
Transfers of liabilities from level 2 to 1
Fair Value Liabilities Level2 To Level1 Transfers Amount
Transfers of assets into level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
Transfers of assets out of level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
Transfers of liabilities into level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
Transfers of liabilities out of level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
Finance lease, right-of-use assets - cost.
Finance lease accumulated amortization.
Operating lease, right-of-use assets - cost.
Operating lease, accumulated amortization.
Finance lease and operating lease assets.
Finance lease and operating lease liability.
Right-of-use assets - cost
Finance Lease Right Of Use Assets Cost
Accumulated amortization
Finance Lease Accumulated Amortization
Finance lease right-of-use assets, net
Right-of-use assets - cost
Operating Lease Right Of Use Assets Cost
Accumulated amortization
Operating Lease Accumulated Amortization
Operating lease right-of-use assets, net
Operating Lease Right Of Use Asset
Total lease assets
Finance Lease And Operating Lease Assets
Finance lease liabilities
Operating lease liabilities
Operating Lease Liability Current
Finance lease liabilities
Operating lease liabilities
Operating Lease Liability Noncurrent
Total lease liabilities
Finance Lease And Operating Lease Liability
Finance lease cost:
Lease Cost [Abstract]
Amortization of right-of-use assets
Interest on lease liabilities
Finance Lease Interest Expense
Operating lease cost
Operating Lease Cost
Sublease income
Sublease Income
Total lease cost
Lease Cost
Cash paid for amounts included in the measurement of lease liabilities.
Right-of-use assets obtained in exchange for new lease liabilities.
Cash paid for amounts included in the measurement of lease liabilities:
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Operating cash flows from operating leases
Operating Lease Payments
Operating cash flows from finance leases
Finance Lease Interest Payment On Liability
Financing cash flows from finance leases
Right-of-use assets obtained in exchange for new lease liabilities:
Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]
Finance leases
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
Operating leases
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
Weighted-average remaining lease term.
Weighted-average discount rate.
Weighted-average remaining lease term (years):
Weighted Average Remaining Lease Term [Abstract]
Finance leases
Finance Lease Weighted Average Remaining Lease Term1
Operating leases
Operating Lease Weighted Average Remaining Lease Term1
Weighted-average discount rate:
Weighted Average Discount Rate [Abstract]
Finance leases
Finance Lease Weighted Average Discount Rate Percent
Operating leases
Operating Lease Weighted Average Discount Rate Percent
Finance Leases
Finance Lease Liabilities Payments Due [Abstract]
2020 (Remaining three month period)
Finance Lease Liability Payments Remainder Of Fiscal Year
2021
Finance Lease Liability Payments Due Next Twelve Months
2022
Finance Lease Liability Payments Due Year Two
2023
Finance Lease Liability Payments Due Year Three
Total future lease payments
Finance Lease Liability Payments Due
Less: Interest
Finance Lease Liability Undiscounted Excess Amount
Present value of lease liabilities
Finance Lease Liability
Operating Leases
Operating Lease Liabilities Payments Due [Abstract]
2020 (Remaining three month period)
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
2021
Lessee Operating Lease Liability Payments Due Next Twelve Months
2022
Lessee Operating Lease Liability Payments Due Year Two
2023
Lessee Operating Lease Liability Payments Due Year Three
Total future lease payments
Lessee Operating Lease Liability Payments Due
Less: Interest
Lessee Operating Lease Liability Undiscounted Excess Amount
Present value of lease liabilities
Operating Lease Liability
Cash And Cash Equivalents [Abstract]
Cash
Cash
Money market funds
Money Market Funds At Carrying Value
Total cash and cash equivalents
Schedule Of Investments [Abstract]
Schedule Of Available For Sale Securities [Table]
Schedule Of Available For Sale Securities [Table]
Geographic Distribution
Geographic Distribution [Axis]
Geographic Distribution
Geographic Distribution [Domain]
Foreign subsidiaries [Member]
Geographic Distribution Foreign [Member]
Long-Term Liabilities [Member]
Schedule of Available-for-sale Securities [Line Items]
Schedule Of Available For Sale Securities [Line Items]
Accrued Liabilities Current [Abstract]
Amortized Cost
Available For Sale Securities Amortized Cost
Gross Unrealized Holding Gains
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
Gross Unrealized Holding Losses
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
Fair Value
Represents the maximum contractual maturity period for available-for-sale securities.
Contractual maturities of available-for-sale investments
Available For Sale Securities Contractual Maturity Period
Other-than-temporary impairment loss
Other Than Temporary Impairment Losses Investments Availableforsale Securities
Raw materials
Inventory Raw Materials
Work-in-progress
Inventory Work In Process
Finished goods
Inventory Finished Goods
Total inventories
Provision to write-down excess and obsolete inventory
Inventory Valuation Reserves
Supplies, net.
Prepaid Expense And Other Assets Current [Abstract]
Unbilled contract assets
Deferred revenues from associated contracts
Net unbilled contract assets
Supplies Net
Prepaid assets
Prepaid Expense Current
Other current assets
Other Assets Current
Total prepaid expenses and other current assets
Number of regulatory milestones.
Number of regulatory milestones
Number Of Regulatory Milestones
Billed contract assets
Billed Contract Receivables
Property Plant And Equipment [Abstract]
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Leasehold improvements [Member]
Leasehold Improvements [Member]
Laboratory equipment.
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Machinery [Member]
Machinery And Equipment [Member]
Computer Equipment [Member]
Computer Equipment [Member]
Furniture and Fixtures [Member]
Furniture And Fixtures [Member]
Construction in progress [Member]
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less: accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Property and equipment, net
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued active pharmaceutical ingredient product price adjustment current.
Accrued co-promotion expenses - current.
Property taxes and other current.
Preclinical and clinical trial accruals
Accrued Preclinical And Clinical Trial Current
API product price adjustment
Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current
Payroll and related accruals
Employee Related Liabilities Current
Accrued co-promotion expenses - current
Accrued Co Promotion Expenses Current
Property taxes and other
Property Taxes And Other Current
Professional services
Accrued Professional Fees Current
Other
Other Accrued Liabilities Current
Total accrued and other current liabilities
Accrued Liabilities Current
API product price change in estimated variable consideration
Other Liabilities Noncurrent [Abstract]
Other long-term tax liabilities
Deferred Tax And Other Liabilities Noncurrent
Operating lease liabilities, non-current
Other
Other Sundry Liabilities Noncurrent
Total other long-term liabilities
Reversal of previously accrued long term co promotion expenses.
Reversal of previously accrued long-term co-promotion expenses
Reversal Of Previously Accrued Long Term Co Promotion Expenses
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Research and development [Member]
Research And Development Expense [Member]
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense
Allocated Share Based Compensation Expense
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Employee stock options [Member]
Employee Stock Option [Member]
2014 Employee Share Purchase Plan [Member]
Stock Compensation Plan [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Expected volatility, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
Expected volatility, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
Risk-free interest rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Risk-free interest rate, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
Risk-free interest rate, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Expected dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Weighted average estimated fair value
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Schedule Of Related Party Transactions By Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Astellas.
Astellas [Member]
Astellas [Member]
Collaborative Arrangement [Member]
Collaborative Arrangement [Member]
Transaction Type
Transaction Type [Axis]
Transaction
Transaction [Domain]
API shipment.
API Shipment [Member]
A P I Shipment [Member]
Falikang.
Falikang [Member]
Falikang [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Revenue related to collaboration agreements
Revenue From Related Parties
Expense related to collaboration agreements
Related Party Transaction Expenses From Transactions With Related Party
Accrued liabilities to related party
Amount paid to related party
Related Party Transaction Amounts Of Transaction
Net unbilled contract asset
Miscellaneous receivables.
Miscellaneous receivables
Miscellaneous Receivables
Future milestone payments.
Commitments and contingencies.
Commitments and contingencies.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Category of Item Purchased
Long Term Purchase Commitment By Category Of Item Purchased [Axis]
Long-term Purchase Commitment, Category of Item Purchased
Long Term Purchase Commitment Category Of Item Purchased [Domain]
Manufacture and Supply of Roxadustat.
Manufacture and Supply of Roxadustat [Member]
Manufacture And Supply Of Roxadustat [Member]
Research and pre-clinical stage development programs.
Research and Pre-Clinical Stage Development Programs [Member]
Research And Pre Clinical Stage Development Programs [Member]
Other Purchases.
Other Purchases [Member]
Other Purchases [Member]
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Outstanding non-cancelable contract obligations
Contractual Obligation
Future milestone payments
Future Milestone Payments